Skip to main content

Joint HOVON-50/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients

Annals of Hematology volume 82, pages 654–659 (2003)Cite this article

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 39.95

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

References

  1. Alexanian R, Dimopoulos M (1994) The treatment of multiple myeloma. N Engl J Med 330:484–489

    Article  CAS  PubMed  Google Scholar 

  2. Hjorth M, Holmberg E, Rodjer S, Turesson I, Westin J, Wisloff F (1999) Survival in conventionally treated younger (<60 years) multiple myeloma patients no improvement during two decades. Eur J Haematol 62:271–277

    CAS  PubMed  Google Scholar 

  3. Gregory WM, Richards MA and Malpas JS (1992) Combination chemotherapy versus melphalan and prednisone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol 10:334–342

    CAS  PubMed  Google Scholar 

  4. Barlogie B, Jagannath S, Vesole DH, Naucke S, Cheson B, Mattox S, Bracy D, Salmon S, Jacobson J, Crowley J, Tricot G (1997) Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 89:789–793

    CAS  PubMed  Google Scholar 

  5. Tricot G, Jagannath S, Vesole D, Nelson J, Tindle S, Miller L, Cheson B, Crowley J, Barlogie B (1995) Peripheral blood stem cell transplants for multiple myeloma: Identification of favorable variables for rapid engraftment in 225 patients. Blood 85:588–596

    CAS  PubMed  Google Scholar 

  6. Vesole DH, Barlogie B, Jagannath S, Cheson B, Tricot G, Alexanian R, Crowley J (1994) High-dose therapy for refractory multiple myeloma: Improved prognosis with better supportive care and double transplants. Blood 84:950–956

    CAS  PubMed  Google Scholar 

  7. Segeren CM, Sonneveld P, van der Holt B, Baars JW, Biesma DH, Cornellissen JJ, Croockewit AJ, Dekker AW, Fibbe WE, Lowenberg B, van Marwijk Kooy M, van Oers MH, Richel DJ, Schouten HC, Vellenga E, Verhoef GE, Wijermans PW, Wittebol S, Lokhorst HM (1999) Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma. Br J Haematol 105:127–130

    Article  CAS  PubMed  Google Scholar 

  8. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, Casassus P, Maisonneuve H, Facon T, Ifrah N, Payen C, Bataille R (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. New Engl J Med 335:91–97

    Article  CAS  PubMed  Google Scholar 

  9. Harousseau JL (2002) High-dose therapy in multiple myeloma. Ann Oncol 13 [Suppl 4]:49–54

    Google Scholar 

  10. Barlogie B, Jagannath S, Desikan KR, Mattox S, Vesole D, Siegel D, Tricot G, Munshi Fassas A, Singhal S, Mehta J, Anaissie E, Dhodapkar D, Naucke S, Cromer J, Sawyer J, Epstein J, Spoon D, Ayers D, Cheson B, Crowley J (1999) Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 93:55–65

    CAS  PubMed  Google Scholar 

  11. Attal MM, Harousseau JL, Facon T, Michaux JI, Guilhot F, Fruchard CC, Fuzibet JGJG, Hulin CC, Caillot DD, Dorvaux VV, Cahn JY, Grobois BB, Stoppa AMAM, Ifrah NN, Sotto JJ, Pignon BB, Payen CC (2000) Single versus double transplantation in myeloma: a prospective randomized trial of the Inter Groupe Francophone du Myelome (IFM) (abstract). Blood 101:2393a

    Google Scholar 

  12. Fritz E, Ludwig H (2000) Interferon in multiple myeloma: meta-analysis of 30 randomised trials among 3948 patients. Ann Oncol 11:1427–1436

    CAS  PubMed  Google Scholar 

  13. Cunningham D, Powles R, Malpas J, Raje N, Milan S, Viner C, Montes A, Hickish T, Nicoloson M, Johnson P, Treleaven J, Raymond J, Gore M (1998) A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: long-term follow-up results. Br J Haematol 102:495–502

    Article  CAS  PubMed  Google Scholar 

  14. Björkstrand B, Svensson H, Goldschmidt H, Ljungman P, Apperley J, Mandelli F, Marcus R, Boogaerts M, Alegre A, Remis K, Cornelissen JJ, Bladé J, Lenhoff S, Irondo A, Carlson K, Volin L, Littlewood T, Goldstone AH, San Miguel J, Schattenberg A, Gahrton G (2001) Alpha-interferon maintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation in patients with multiple myeloma: a retrospective registry study from the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 27:511–515

    Google Scholar 

  15. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeddis J, Barlogie B (1999) Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341:1565–1571

    CAS  PubMed  Google Scholar 

  16. Juliusson G, Celsing F, Turesson I, Lenhoff S, Adriansson M, Malm C (2000) Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma. Br J Haematol 109:89–96

    CAS  PubMed  Google Scholar 

  17. Rajkumar SV, Witzig TE (2000) A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma. Cancer Treat Rev 26:351–362

    CAS  PubMed  Google Scholar 

  18. Kneller A, Raanani P, Hardan I, Avigdor A, Levi I, Berkowicz M, Ben-Bassat I (2000) Therapy with thalidomide in refractory multiple myeloma. The revival of an old drug. Br J Haematol 108:391–393

    Article  CAS  PubMed  Google Scholar 

  19. Rajkumar SV, Fonseca R, Dispenzieri A, Lacy MQ, Lust JA, Witzig TE, Kyle RA, Gertz MA, Greipp PR (2000) Thalidomide in the treatment of relapsed multiple myeloma. Mayo Clinic Proc 75:897–901

    CAS  Google Scholar 

  20. Neben K, Moehler TM, Egerer G, Kraemer A, Hillengass J, Benner A, Ho AD, Goldschmidt H (2000) High plasma basic fibroblast growth factor (bFGF) concentration is associated with good response to thalidomide monotherapy in progressive multiple myeloma. Blood 101:124a

    Google Scholar 

  21. Moehler TM, Neben K, Ho AD, Goldschmidt H (2001) Angiogenesis in hematologic malignancies. Ann Hematol 80:695–705

    CAS  PubMed  Google Scholar 

  22. Schreiber S, Ackermann J, Obermair a, Kaufmann H, Urbauer E, Aletaha K, Gisslinger H, Chott A, Huber H, Drach J (2000) Multiple myeloma with deletion of chromosome 13q is characterized by increased bone marrow neovascularization. Br J Haematol 110:605–609

    Article  CAS  PubMed  Google Scholar 

  23. Moehler TM, Hawighorst H, Neben K, Benner A, Hillengass J, Egerer G, Max R, Ho AD, Goldschmidt H, van Kaick G (2000) Functional magnetic resonance imaging for detection and monitoring of bone lesions in multiple myeloma. Radiologe 8:723–731

    Article  Google Scholar 

  24. Rajkumar SV, Witzig TE (2000) A review of angiogenesis and antiangiogenic therapy with Thalidomide in multiple myeloma. Cancer Treat Rev 26:351–362

    CAS  PubMed  Google Scholar 

  25. Hattori Y, Kakimoto T (2000) Bone marrow angiogenesis in multiple myeloma: new insights into the pathogenesis, and development of a new therapeutic approach. Rinsho Ketsueki 41:426–429

    CAS  PubMed  Google Scholar 

  26. Hideshima T, Chauhan D, Shima Y, Raje N, Davies FE, Tai YT, Treon SP, Lin B, Schlossmann RL, Richardson P, Muller G, Stirling DI, Anderson KC (2000) Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 96:2943–2950

    CAS  PubMed  Google Scholar 

  27. Munshi N, Desikan R, Zangari M, Badros U, Chodimella U, Toor A, Cromer T, Terry J, Anaissie M, Barlogie B (1999) Chemotherapy with DT-PACE for previously treated multiple myeloma (abstract). Blood 94 [Suppl 1]:123a

  28. Moehler TM, Neben K, Benner A, Egerer G, Krasniqi F, Ho AD, Goldschmidt H (2001) Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy. Blood 15:3846–3848

    Article  Google Scholar 

  29. Zangari M, Anaissie E, Barlogie B, Badros A, Desikan R, Gopal AV, Morris C, Toor A, Siegel E, Fink L, Trico G (2001) Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 98:1614–1615

    Article  CAS  PubMed  Google Scholar 

  30. Pini M, Baraldi A, Pietrasanta D, Allione B, Depaoli L, Salvi F, Levis A (2000) Low-dose of thalidomide in the treatment of refractory myeloma. Haematologica 85:1111–1112

    CAS  PubMed  Google Scholar 

  31. Gahrton G, Svensson H, Cavo M, Apperly J, Bacigalupo A, Bjorkstrand B, Blade J, Cornelissen J, de Laurenzi A, Facon T, Ljungman P, Michallet M, Niederwieser D, Powles R, Reiffers J, Russell NH, Samson D, Schaefer UW, Schattenberg A, Tura S, Verdonck LF, Vernant JP, Willemze R, Volin L (2001) Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983–93 and 1994–8 at European Group for Blood and Marrow Transplantation centers. Br J Haematol 113:209–216

    CAS  PubMed  Google Scholar 

  32. Badros A, Barlogie B, Siegel E, Cottler-Fox M, Zangari M, Fassas A, Morris C, Anaissie E, Van RheeF, Tricot G (2002) Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning. J Clin Oncol 20:1295–1303

    Article  PubMed  Google Scholar 

  33. Chakraverty R, Peggs K, Chopra R, Milligan DW, Kottaridis PD, Verfuerth S, Geary J, Thuraisundaram D, Branson K, Chakrabarti S, Mahendra P, Craddock C, Parker A, Hunter A, Hale G, Waldmann H, Williams CD, Yong K, Linch DC, Goldstone AH, Mackinnon S (2002) Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood 99:1071–1078

    Article  CAS  PubMed  Google Scholar 

  34. Kroger N, Schwerdtfeger R, Kiehl M, Sayer HG, Renges H, Zabelina T, Fehse B, Togel F, Wittkowsky G, Kuse R, Zander AR (2002) Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood 100:755–760

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medizinische Klinik und Poliklinik V, Universität Heidelberg, Hospitalstrasse 3, 69115, Heidelberg, Germany

    H. Goldschmidt, F. W. Cremer, I. Breitkreutz & A. D. Ho

  2. Department of Hematology, University Hospital Rotterdam, Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands

    P. Sonneveld

  3. HOVON Data Center, University Hospital Rotterdam, Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands

    B. van der Holt & P. Westveer

  4. Zentraleinheit Biostatistik, Deutsches Krebsforschungszentrum, Im Neuenheimer Feld 280, 69120, Heidelberg, Germany

    A. Benner

  5. Medizinische Universitätsklinik und Poliklinik I, Sigmund-Freud-Strasse 25, 53105, Bonn, Germany

    A. Glasmacher & I. G. D. Schmidt-Wolf

  6. Medizinische Klinik III, Universitätsklinik Frankfurt, Theodor-Stern-Kai 7, 60596, Frankfurt, Germany

    H. Martin & D. Hoelzer

  7. Department of Hematology, University Hospital Utrecht, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands

    H. M. Lokhorst

Authors
  1. H. Goldschmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. Sonneveld
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F. W. Cremer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. B. van der Holt
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P. Westveer
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. I. Breitkreutz
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A. Benner
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A. Glasmacher
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. I. G. D. Schmidt-Wolf
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. H. Martin
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. D. Hoelzer
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. A. D. Ho
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. H. M. Lokhorst
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H. Goldschmidt.

Additional information

HOVON protocol committee and coordinators:

Principal investigators HOVON: H.M. Lokhorst, P. Sonneveld

Protocol committee: J. W. Baars (A. van Leeuwenhoek Hospital, Amsterdam), R. Barge (University Medical Center, Leiden), G. Bos (University Hospital Maastricht), J. J. Cornelissen (University Hospital Rotterdam), A. J. Croockewit (University Hospital Nijmegen), P. C. Huijgens (University Hospital Free University, Amsterdam), P. Joosten (Medical Center, Leeuwarden), H. M. Lokhorst (University Hospital Utrecht), M. van Marwijk Kooy (Isala Clinic-Sophia, Amsterdam), M. R. Schaafsma (Medical Center Twente, Enschede), P. Sonneveld (University Hospital Rotterdam), H. Sinnige (Bosch Medical Center, Den Bosch), E. Vellenga (University Hospital Groningen), G. Verhoef (University Hospital Leuven), O. de Weerd (St Antonius Hospital Nieuwegein), P. Wijermans (Leyenburg Hospital, The Hague), S. Wittebol (Hospital Eemland, Amersfoort)

Randomization: HOVON Data Center (Tel.: +31-10-4391568)

Study data center: HOVON Data Center, University Hospital Rotterdam-Daniel, P.O. Box 5201, 3008 Rotterdam

GMMG protocol committee and coordinators:

Principal investigator GMMG: H. Goldschmidt

Protocol committee: A. D. Ho (University Hospital Heidelberg), A. Glasmacher (University Hospital Bonn), I.G.D. Schmidt-Wolf (University Hospital Bonn), H. Martin (University Hospital Frankfurt), D. Hoelzer (University Hospital Frankfurt)

Randomization: ZE Biostatistik, Deutsches Krebsforschungszentrum (Fax: +49-6221-42522390)

Study data center: GMMG-Studiensekretariat, O. Kien, S. Pignotti, M. Schäffner-Fank, I. Breitkreutz, Medizinische Klinik und Poliklinik V, Universität Heidelberg, Hospitalstrasse 3, 69115 Heidelberg (e-mail: studiensekretariat_GMMG@med.uni-heidelberg.de, Tel.: +49-6221-568198, Fax: +49-6221-561957)

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Goldschmidt, H., Sonneveld, P., Cremer, F.W. et al. Joint HOVON-50/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients. Ann Hematol 82, 654–659 (2003). https://doi.org/10.1007/s00277-003-0685-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-003-0685-2

Keywords

  • Overall Survival
  • Multiple Myeloma
  • Thalidomide
  • Allogeneic Transplantation
  • Peripheral Blood Stem Cell Transplantation